secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coya Therapeutics, Inc. (COYA)
CIK:        0001835022
Form:       8-K
Filed at:   2023-07-14T23:59:59+00:00
Accession:  0001193125-23-187328
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coya Therapeutics appoints Dr. Fred Grossman as President and CMO; compensation terms disclosed
--------------------------------------------------------------------------------

- Base salary of $450,000/year; annual bonus target of 40% of base salary based on company/individual performance.
- Two option grants of 74,069 each (start date and Jan 2024) vesting over 3 years; additional equity possible.
- Severance: 9 months base salary plus 9 months accelerated vesting if terminated without cause or resigns for good reason.
- Employment effective July 17, 2023; initial term 2 years with auto-renewal.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835022/000119312523187328/0001193125-23-187328-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835022/000119312523187328/d499175d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-187328

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer